Peptide · Fact sheet
BPC-157
Also known as Body Protection Compound 157
BPC-157 is often promoted for injury or gut healing, but it is not an FDA-approved medicine and reliable human clinical evidence is extremely limited.
What is BPC-157?
BPC-157 is a synthetic sequence described as being derived from a gastric protein fragment.
Claims about healing are largely extrapolated from animal and laboratory studies, which cannot show that the same benefits or risks apply to people.
Benefits people look for
Online discussions frequently mention tendon, ligament, muscle, bone, nerve, and gastrointestinal recovery.
The gap between confident marketing and sparse human evidence is the central fact readers should understand.
What the evidence supports
- Animal and laboratory studies have reported signals related to tissue repair and inflammation.
- Those findings are hypotheses for human research, not proven patient benefits.
All research areas
- Acute hamstring strain in a registered Phase 2 trial
- Tissue repair in animal models
- Gastrointestinal effects in animal models
- Inflammation and blood-vessel signaling in preclinical research
- Acute hamstring-strain repair in a registered trial
- Preclinical models of tissue injury and gastrointestinal conditions
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
Less knee pain during combined exposure
One person attributed a gradual reduction in longstanding knee pain to products labeled BPC-157 and TB-500 used together.
Two products were used, with no control group or independent assessment of healing. The account cannot separate their effects. TB-500 product labeling does not verify equivalence to full-length thymosin beta-4.
Read the knee-pain report ↗Severe anxiety, sleeplessness and chest tightness
A different person reported these symptoms after exposure to products labeled BPC-157 and TB-500, including seeking hospital assessment.
Combined exposure and unverified product identity prevent attribution to either substance. This is a personal report, not a confirmed drug reaction or an estimate of risk.
Read the adverse-experience report ↗Nausea, fatigue, anxiety and fainting
A separate poster described nausea, marked tiredness, increased anxiety and passing out during exercise after starting a product labeled BPC-157.
The poster later described an abnormal ECG but explicitly questioned whether BPC-157 explained it. No medical records or product testing were verified.
Read the separate BPC-157 account ↗Side effects & risks
- Human short- and long-term safety are poorly characterized.
- FDA notes possible immune reactions, peptide-related impurities, and difficulty characterizing the active ingredient.
- Unapproved products may introduce contamination, incorrect-strength, sterility, or mislabeling risks.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Mostly animal or lab researchMost cited work is preclinical. There is no mature body of randomized human trials establishing safety and effectiveness for common promoted uses.
Selected research to read
Registry record for an early human BPC-157 study, not evidence of established clinical benefit.
Peer-reviewed review focused largely on preclinical BPC-157 research.
Review discussing BPC-157 wound-healing research, primarily outside mature human efficacy trials.
FDA approval & research status
BPC-157 is not FDA approved. A Phase 2 hamstring-strain trial is registered, and FDA lists BPC-157 among bulk substances for which compounded products may present significant safety risks and for which safety information is limited.
No FDA-approved use is documented in the records summarized on this page.
Early human clinical testing
A Phase 2 hamstring-strain trial is registered, but no BPC-157 product is FDA approved and the published evidence base remains mostly preclinical.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether animal findings translate to meaningful human benefits
- Long-term safety, cancer-related signaling concerns, interactions, and reproductive risks
- A reliable adverse-effect rate or risk profile
- Whether products sold under the name consistently contain the claimed substance
The takeaway
BPC-157 is a striking example of online certainty outrunning human evidence. Preclinical findings are not a substitute for controlled trials or regulatory review.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2clinical trialsClinicalTrials.gov: BPC-157 hamstring strain study
Registry record for an early human BPC-157 study, not evidence of established clinical benefit.
- 3pubmedBPC-157 preclinical gastrointestinal review
Peer-reviewed review focused largely on preclinical BPC-157 research.
- 4pubmedBPC-157 wound-healing review
Review discussing BPC-157 wound-healing research, primarily outside mature human efficacy trials.